Drug Trial Radar · NCT01626573
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Mar 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Mar 2012
Primary completion
Jul 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jun 22, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.
Conditions
- Rheumatoid Arthritis
Interventions
ItacitinibDrug
Itacitinib PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of itacitinib as assessed by the changes in frequency and severity of adverse events, ECGs, vital signs, physical examinations, and clinical laboratory evaluations.Time frame: Approximately four months.
- Preliminary efficacy as assessed by the percentage of patients achieving ACR20 improvement from baseline on the day 28 and day 84 visits.Time frame: Approximately 84 days.
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Palm Desert, California
Site not named
Pasadena, California
Site not named
Lake Mary, Florida
Site not named
Ocala, Florida
Site not named
Palm Harbor, Florida
Site not named
Tampa, Florida
Site not named
Tavares, Florida
Site not named
Lexington, Kentucky
Site not named
Worcester, Massachusetts
Site not named
Lansing, Michigan
Site not named
Raleigh, North Carolina
Site not named
Middleburg Heights, Ohio
Site not named
Duncansville, Pennsylvania
Site not named
Florence, South Carolina
Site not named
Austin, Texas
Site not named
Katy, Texas
Site not named
Spokane, Washington
Site not named
Carolina, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.